Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23765253 | 1.00 | ALDH1A1 (0.33) | ALDH1A1TDP1CHRM2CHRM1CHRM3 | |
| SCHEMBL23765298 | 1.00 | ALDH1A1 (0.33) | ALDH1A1TDP1CHRM2CHRM1CHRM3 | |
| SCHEMBL25520261 | 0.86 | — | — | |
| SCHEMBL2125652 | 0.84 | ALDH1A1 (0.36) | ALDH1A1TDP1USP2GAAMAPT | |
| SCHEMBL20900595 | 0.81 | CHRM2 (0.31) | ALDH1A1TDP1CHRM2CHRM1CHRM3 | |
| SCHEMBL20381734 | 0.81 | CHRM2 (0.31) | ALDH1A1TDP1CHRM2CHRM1CHRM3 | |
| SCHEMBL1091004 | 0.78 | APLNR (0.33) | — | |
| SCHEMBL17465649 | 0.78 | ALDH1A1 (0.37) | ALDH1A1TDP1 | |
| SCHEMBL20402853 | 0.78 | CHRM2 (0.32) | CHRM2CHRM1CHRM3 | |
| SCHEMBL22623987 | 0.78 | KDM4E (0.41) | CHRM2CHRM1CHRM3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-11667673-B2 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667673-B2 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230159466-A1 | INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159466-A1 | INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| US-20230143050-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2023-05-11 | — | — | US | disclosed |
| US-11591355-B2 | CD73 inhibitors and uses thereof | PELOTON THERAPEUTICS INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | Halia Therapeutics, Inc. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20130079412-A1 | Branched 3-phenylpropionic acid derivatives and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-03-28 | — | — | US | disclosed |
| US-8304403-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120172448-A1 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-05 | — | — | US | disclosed |
| US-20120172448-A1 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-05 | — | — | US | disclosed |
| US-20110130445-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | disclosed |
| US-7888376-B2 | Cholesteryl ester transfer protein (CETP) inhibitors; atherosclerosis and cardiovascular diseases; N-(1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-4-(trifluoromethyl)thiazol-2-amine; Alzheimer's, atherosclerosis, venous thrombosis, peripheral vascular disease | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-15 | — | — | US | disclosed |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-7790770-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ALDH1A1 2353/4885TDP1 610/4885CHRM2 4616/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ALDH1A1 2353/4885TDP1 610/4885CHRM2 4616/4885 |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PRKAR2B | ALDH1A1 2661/4885TDP1 448/4885CHRM2 1406/4885 |
| US-20130079412-A1 | Branched 3-phenylpropionic acid derivatives and their use | PC, FABP3, PCCA | ALDH1A1 641/4885TDP1 1678/4885CHRM2 1039/4885 |
| US-20110130445-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | FABP3, PC, PAH | ALDH1A1 431/4885TDP1 1209/4885CHRM2 1331/4885 |
| US-20230143050-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | IL17A, IL23R, IL15 | ALDH1A1 144/4885TDP1 3324/4885CHRM2 2463/4885 |
| US-11667673-B2 | Therapeutically active compounds and their methods of use | IDH1, IDH3B, IDH3A | ALDH1A1 413/4885TDP1 301/4885CHRM2 4844/4885 |
| US-11591355-B2 | CD73 inhibitors and uses thereof | ENTPD5, ENTPD1, ENTPD3 | ALDH1A1 619/4885TDP1 192/4885CHRM2 119/4885 |
| US-20230159466-A1 | INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN2 | ALDH1A1 600/4885TDP1 3056/4885CHRM2 4866/4885 |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | LRRK2, SNCA, PRKAR2B | ALDH1A1 2661/4885TDP1 448/4885CHRM2 1406/4885 |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ALDH1A1 2353/4885TDP1 610/4885CHRM2 4616/4885 |
| US-20120172448-A1 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof | PC, ACACA, PCCA | ALDH1A1 419/4885TDP1 3103/4885CHRM2 2229/4885 |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1B, SCN1A, SCN2B | ALDH1A1 1828/4885TDP1 1890/4885CHRM2 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.